Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (91)

2024

  1. Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921

  2. Generation of Self-Induced Myocardial Ischemia in Large-Sized Cardiac Spheroids without Alteration of Environmental Conditions Recreates Fibrotic Remodeling and Tissue Stiffening Revealed by Constriction Assays

    ACS Biomaterials Science and Engineering, Vol. 10, Núm. 2, pp. 987-997

  3. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

    Clinical and Translational Oncology

  4. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 1080-1093

  5. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  6. Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

    International journal of molecular sciences, Vol. 25, Núm. 8

2023

  1. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress

    Cells, Vol. 12, Núm. 18

  2. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

  3. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

  4. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma

    Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65

  5. Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

    Haematologica, Vol. 108, Núm. 10, pp. 2652-2663

  6. Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  7. Loss of the matrix metalloproteinase-10 causes premature features of aging in satellite cells

    Frontiers in Cell and Developmental Biology, Vol. 11

  8. Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5P

    Atherosclerosis, Vol. 385

  9. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

    Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467

  10. When and How to Use Reversal Agents for Direct Oral Anticoagulants?

    Current Cardiology Reports, Vol. 25, Núm. 5, pp. 371-380

2022

  1. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

  2. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism

    Cancers, Vol. 14, Núm. 17

  3. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

  4. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer

    HemaSphere, Vol. 6, Núm. 8